Data from a small study show that severe methotrexate toxicity in patients who are 70 years of age and older and have rheumatic disease may be associated with poor renal function and the use of diuretic treatments.
Zoledronic Acid vs. Oral Bisphosphonates: Osteoporosis Treatments & the Risk of Developing Osteonecrosis of the Jaw
A study from Amigues et al. found that bisphosphonate-associated osteonecrosis of the jaw is rare in patients with osteoporosis and may occur more often in patients treated with injectable zoledronic acid than in those treated with the oral bisphosphonates.
Patients on Dialysis Taking Denosumab May Be at Risk of Severe Hypocalcemia
The FDA is investigating the risk of severe hypocalcemia with serious outcomes, such as hospitalization and death, in patients on dialysis taking denosumab.
CORRONA: History & Lessons Learned
Editor’s note: In November, the ACR honored Joel M. Kremer, MD, MACR, president of the Corrona Research Foundation, with its Distinguished Clinical Investigator Award for his outstanding contributions to the field of rheumatology as a clinical scientist (see story here). As the founder of the Consortium of Rheumatology Researchers of North America (CORRONA, now known…
Rheumatology Medications with Limited Safety Data: How Do We Use Them in Pregnant Patients?
How does a rheumatologist treat a pregnant woman when many medications are not approved for pregnancy or safety data are limited?
The Complexity of SLE Drug Research
PHILADELPHIA—On Saturday, Nov. 12, at ACR Convergence 2022, Joan T. Merrill, MD, director of clinical projects in the Arthritis & Clinical Immunology Program at the Oklahoma Medical Research Foundation in Oklahoma City, gave a presentation on the future of drug development and treatments for systemic lupus erythematosus (SLE). She described how an in-depth understanding of…
Considering Benzbromarone as First-Line Therapy for Gout
In this comparative effectiveness clinical trial, Yan et al. set out to compare nontitrated, low-dose benzbromarone (not approved in the U.S.), a renal urate transporter 1 inhibitor, with low-dose febuxostat as the first-line therapy in gout patients with renal uric acid underexcretion.
FDA Approves Ustekinumab for Children with PsA
After examining study data from pediatric patients with both psoriasis and psoriatic arthritis (PsA), the FDA approved ustekinumab as a treatment for patients aged 6–17 years old with PsA.
TNF Inhibitors Associated with Neurological Adverse Events
A study examined the association between TNF inhibitors and neurological demyelinating adverse events in patients with rheumatoid arthritis and spondyloarthritis using cohort data from five Nordic countries. Researchers showed that patients with SpA were more likely to experience adverse events than patients with RA.
Speak Out Rheum: How Did We Go So Wrong with Opioid Prescribing?
I have been listening to The Fighter Pilot Podcast because my fantasy career would have been to fly a jet fighter plane (not even remotely possible, given my constitution). I learned that when an aircraft accident occurs, a mishap board is convened, not to assign blame but to try to learn what went wrong and…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 120
- Next Page »